Skip to Content
Merck
  • Inhibitory effects of French pine bark extract, Pycnogenol®, on alveolar bone resorption and on the osteoclast differentiation.

Inhibitory effects of French pine bark extract, Pycnogenol®, on alveolar bone resorption and on the osteoclast differentiation.

Phytotherapy research : PTR (2014-10-23)
Hideki Sugimoto, Kiyoko Watanabe, Toshizo Toyama, Shun-suke Takahashi, Shuta Sugiyama, Masaichi-Chang-il Lee, Nobushiro Hamada
ABSTRACT

Pycnogenol(®) (PYC) is a standardized bark extract from French maritime pine (Pinus pinaster Aiton). We examined the inhibitory effects of PYC on alveolar bone resorption, which is a characteristic feature of periodontitis, induced by Porphyromonas gingivalis (P. gingivalis) and osteoclast differentiation. In rat periodontitis model, rats were divided into four groups: group A served as the non-infected control, group B was infected orally with P. gingivalis ATCC 33277, group C was administered PYC in the diet (0.025%: w/w), and group D was infected with P. gingivalis and administered PYC. Administration of PYC along with P. gingivalis infection significantly reduced alveolar bone resorption. Treatment of P. gingivalis with 1 µg/ml PYC reduced the number of viable bacterial cells. Addition of PYC to epithelial cells inhibited adhesion and invasion by P. gingivalis. The effect of PYC on osteoclast formation was confirmed by tartrate-resistant acid phosphatase staining. PYC treatment significantly inhibited osteoclast formation. Addition of PYC (1-100 µg/ml) to purified osteoclasts culture induced cell apoptosis. These results suggest that PYC may prevent alveolar bone resorption through its antibacterial activity against P. gingivalis and by suppressing osteoclastogenesis. Therefore, PYC may be useful as a therapeutic and preventative agent for bone diseases such as periodontitis.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Trimethoprim, ≥99.0% (HPLC)
Supelco
Trimethoprim, VETRANAL®, analytical standard
Sigma-Aldrich
Prostaglandin E2, ≥93% (HPLC), synthetic
Sigma-Aldrich
Prostaglandin E2, γ-irradiated, powder, BioXtra, suitable for cell culture
Sigma-Aldrich
Trimethoprim, ≥98.5%
Sigma-Aldrich
Prostaglandin E2, synthetic, powder, BioReagent, suitable for cell culture
Supelco
Trimethoprim, Pharmaceutical Secondary Standard; Certified Reference Material
Calcitriol, European Pharmacopoeia (EP) Reference Standard
USP
Trimethoprim, United States Pharmacopeia (USP) Reference Standard
Dexamethasone for peak identification, European Pharmacopoeia (EP) Reference Standard
Trimethoprim, European Pharmacopoeia (EP) Reference Standard
Supelco
Dexamethasone, VETRANAL®, analytical standard
Supelco
Sulfamethoxazole, VETRANAL®, analytical standard
Sigma-Aldrich
1α,25-Dihydroxyvitamin D3, ≥99% (HPLC)
Sigma-Aldrich
Dexamethasone, powder, BioReagent, suitable for cell culture, ≥97%
Sigma-Aldrich
Dexamethasone, meets USP testing specifications
Sigma-Aldrich
Dexamethasone, ≥98% (HPLC), powder
Sigma-Aldrich
Dexamethasone, powder, γ-irradiated, BioXtra, suitable for cell culture, ≥80% (HPLC)
Supelco
Sulfamethoxazole
Sigma-Aldrich
Dexamethasone, tested according to Ph. Eur.
Sigma-Aldrich
1α,25-Dihydroxyvitamin D3, ≥97.0% (HPLC)
Supelco
Sulfamethoxazole, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
Supelco
Sulfamethoxazole, Pharmaceutical Secondary Standard; Certified Reference Material
Dexamethasone, European Pharmacopoeia (EP) Reference Standard
USP
Dexamethasone, United States Pharmacopeia (USP) Reference Standard
Supelco
Dexamethasone, Pharmaceutical Secondary Standard; Certified Reference Material
Dinoprostone, European Pharmacopoeia (EP) Reference Standard
Dexamethasone for system suitability, European Pharmacopoeia (EP) Reference Standard
Sulfamethoxazole, European Pharmacopoeia (EP) Reference Standard
Trimethoprim for system suitability, European Pharmacopoeia (EP) Reference Standard